|
|
|
|
Vol. 57, Issue 4, 725-731, April 2000
-Opioid Receptor Gene Function In
Vivo by Peptide Nucleic Acids
AstraZeneca R & D Montréal, Quebec, Canada (G.L.F., J.H.);
Department of Pharmacology and Therapeutics, McGill University,
Montreal, Quebec, Canada (G.L.F., P.B.S.C., C.W.); and Center for
Genomics Research, Karolinska Institutet, Stockholm, Sweden (C.W.)
Peptide nucleic acids (PNA) are synthetic analogs of DNA that
hybridize to complementary oligonucleotide sequences with exceptional affinity and target specificity. The stability of PNA in biological fluids together with the unique hybridization characteristics of these
structures suggests that PNA may have considerable potential as
antisense agents for experimental use in vivo. To test this hypothesis,
we attempted to modulate supraspinal
-opioid receptor function in
rats using PNA sequences designed to be complementary to a region of
the rat
-opioid receptor. Repeated i.c.v. administration of PNA over
a period of 5 days significantly inhibited the antinociceptive response
and locomotor response to selective
-opioid receptor agonists. PNA
attenuated
-opioid receptor function in a sequence-specific, target-specific, and reversible manner characteristic of the functional inhibition caused by an antisense mechanism. There were no apparent toxicities arising from the PNA treatment based on the behavior of the
animals and inspection of the treated tissues. Saturation binding
studies on brain homogenates did not reveal any significant difference in receptor Bmax between
treatment groups. However, [35S]guanosine-5'-O-(3-thio)triphosphate
binding assays demonstrated a significant decrease in agonist efficacy
in homogenates prepared from antisense-treated rats. Taken together,
these results demonstrate that peptide nucleic acids are effective
antisense agents in vivo and suggest that PNA may be a useful
alternative to phosphodiester or phosphorothioate oligonucleotides, or
variants thereof, for determination of gene function in vivo.
This article has been cited by other articles:
![]() |
V. Rapozzi, B. E. A. Burm, S. Cogoi, G. A. van der Marel, J. H. van Boom, F. Quadrifoglio, and L. E. Xodo Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids Nucleic Acids Res., September 1, 2002; 30(17): 3712 - 3721. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kaushik, T. T. Talele, R. Monel, P. Palumbo, and V. N. Pandey Destabilization of tRNA3Lys from the primer-binding site of HIV-1 genome by anti-A loop polyamide nucleotide analog Nucleic Acids Res., December 15, 2001; 29(24): 5099 - 5106. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Muratovska, R. N. Lightowlers, R. W. Taylor, D. M. Turnbull, R. A. J. Smith, J. A. Wilce, S. W. Martin, and M. P. Murphy Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease Nucleic Acids Res., May 1, 2001; 29(9): 1852 - 1863. [Abstract] [Full Text] [PDF] |
||||